Today, on World COPD Day, we are excited to share the results of the HOT-HMV trial presented at ERS, which show that HMV added to HOT can reduce by 51% the likelihood of readmissions to hospital or death over one year in hypercapnic COPD patients following an acute exacerbation of COPD.1 There are new prospects for better treatment of COPD—and better lives for patients.
Like all forms of mechanical ventilation, non-invasive ventilation supports a patient’s breathing. It has 2 key goals:
Non-invasive ventilation (NIV) achieves these 2 goals without the adverse effects of invasive ventilation, such as patient discomfort, the loss of airway defence mechanisms, and risks of infection.2
Non-invasive ventilation makes breathing easier by:
Short-term non-invasive ventilation is well-established in treating patients hospitalised with acute exacerbations of COPD.2,3,4
Recent evidence now also shows that when non-invasive ventilation is applied to reduce hypercapnia in COPD patients being treated at home, improvements may be observed in:
Together, this represents a stronger claim for the use of non-invasive ventilation in treating selected COPD patients. Whether it’s used in acute hospital care or for long-term treatment at home, ResMed has taken these findings to develop intelligent non-invasive ventilation solutions to better treat your COPD patients.
Learn more about ResMed’s non-invasive ventilation solutions for COPD.
* World Health Organization. “Chronic respiratory diseases: Burden of COPD” Who.int. https://www.who.int/data/gho/publications/world-health-statistics (accessed November 9, 2015)